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Reformulation of beclomethasone dipropionate (BDP) in the chlorofluorocarbon (CFC)-free propellant 
hydrofluoroalkane-134a (HFA) gave the opportunity to produce a solution formulation that provides a 
greater total mass of fine drug particles than the current CFC suspension metered dose inhaler (MDI). 
The HFA-BDP MD1 was studied in three pharmacokinetic trials in asthmatic patients. Serum levels of 
BDP plus metabolites [total beclomethasone (total BOH) assay] were used to test whether the increased 
fine particle mass of HFA-BDP would result in improved intrapulmonary deposition and subsequent dif- 
ferences in serum profiles. Serum levels, maximum serum concentrations and area under the serum 
concentration-time curves of total BOH following both single and multiple doses of HFA-BDP were sim- 
ilar to those obtained with approximately twice the dose of CFC-BDP. The observed lower bioavailabil- 
ity of CFCBDP compared with HFA-BDP could be explained if most of each inhaled dose from the 
CFC-BDP MD1 was swallowed and absorbed from the gastrointestinal tract, while most of each inhaled 
dose from the HFA-BDP MD1 was absorbed from the lungs. Deposition studies have confirmed this 
explanation. These results suggest that asthmatic patients can be treated with lower total daily doses of 
drug from HFA-BDP extrafine aerosol than from CFC-BDP. 
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Introduction 
Hydrofluoroalkane-134a (HFA) has been shown to be 
a safe replacement for chlorofluorocarbons (CFCs) as 
a pharmaceutical propellant, with the advantage that 
it has no ozone-depleting potential (1). This propellant 
was successfully used in the formulating of a salbuta- 
mol sulphate metered dose inhaler (MDI), marketed 
as AiromirTM or EpaqTM in Europe, New Zealand and 
Asia and as Proventil-HFArM in the U.S.A. The re- 
formulation of beclomethasone dipropionate (BDP) 
in HFA provided the opportunity to modify the phys- 
ical characteristics of the aerosol formulation in view 
of current understanding of pulmonary deposition, 
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making significant changes from the CFC-BDP for- 
mulation that was developed 20 years ago. 
BDP formulated in HFA is a solution with no added 
surfactant; the commercial CFC-BDP formulation, in 
contrast, is a suspension consisting of a mixture of 
two CFC propellants and a surfactant (2). The 
HFA-BDP solution MD1 delivers an aerosol with par- 
ticles of mass mean aerodynamic diameter (mmad) of 
1.1 pm when the MD1 is activated and the propellant 
evaporates, while the CFC-BDP suspension MD1 
delivers particles with mmad of 3.5-4.0 pm (2). 
Furthermore, 52% of the particles delivered by the 
HFA-BDP extrafine aerosol are in the fine particle 
range (~4.7 pm), compared with only 34.5% of the 
particles from the CFCBDP MD1 (3). Because fine 
particle mass has been associated with the amount of 
drug deposited in the lungs, it was predicted that the 
HFA-BDP extrafine aerosol would be likely to deposit 
more drug in the airways than the CFCBDP product. 
The studies described in this review investigated 
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whether differences in fine particle mass observed in 
the laboratory studies of these two propellant formu- 
lations resulted in measurable differences in pharma- 
cokinetics. Significant differences in serum profiles 
between HFA-BDP and CFC-BDP would support 
the hypothesis that increased fine particle mass results 
in increased airway deposition of drug and subsequent 
differences in absorption characteristics. 
The pharmacokinetic studies measured serum levels 
of beclomethasone directly (BOH) or following hydrol- 
ysis (total BOH). The total BOH fraction consists of 
the contributions from BDP and its metabolites (17- 
monopropionate, 21 -monopropionate and BOH) 
present in the serum following hydrolysis of all compo- 
nents in the sample to BOH. At the time of these stud- 
ies, assays for the individual components of the total 
BOH fraction were not available. More than 75% of 
the material in the total BOH fraction at all sampling 
times is derived from&&metbasone Wniiiopropi- 
onate (unpub~EErvation), the most pharmaco- 
logically active component (4), so the total BOH assay 
appears to be representative of active BDP metabolites. 
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TABLE 1. Study outlines 
Study Number Design 
of patients 
Dosage Objective 
Studies Reviewed 
The patient population was standardized across the 
studies included in this review. Males and females, 
aged 18-60 years, with a history of mild to moderate 
asthma controlled by an inhaled P-agonist, were 
included in the studies. Patients had never smoked or 
had abstained from smoking for at least 1 year. All 
were within f20% of ideal body weight and were 
steroid naive (had not received any steroids for the 
past 3 months). All were able to use a press-and- 
breathe MD1 satisfactorily, had a forced expiratory 
volume in 1 s 2 60-70% of predicted normal after 
withholding all asthma therapy for 8 h, and had 
demonstrated reversibility of 2 15% within 30 min of 
administration of an inhaled bronchodilator (salbuta- 
mol or pirbuterol). 
The objectives and designs of the three studies are 
given in Table 1. Similar procedures were used in all 
studies. Medications were self-administered by the 
patients. All dosing procedures were monitored and 
timed by a study coordinator. Inhalations began at the 
same time of day (+15 min) in each period and used a 
standardized inhalation technique. Patients held their 
breath for 10 s following each inhalation and waited a 
total of 30 s before taking the next inhalation. Time 
zero for each dose was defined as the time when the 
MD1 was first actuated. 
BOH serum concentrations were measured in stud- 
ies A and C with the use of a liquid chromatograph 
equipped with a triple quadrapole mass spectrometer. 
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FIG. 1. Mean serum BOH (U, 0) and total BOH (m, 
0) concentrations after single inhaled doses of 
HFA-BDP (0, H, 200 ug; 0, 0,400 ug). 
The analytical range for this method was O.OlO- 
0.300 ng ml-l. Serum total BOH concentrations were 
measured in studies A and B by separating the analytes 
from the serum by liquid-liquid extraction and then 
hydrolysing the extracts to convert BDP and any mono- 
propionates to BOH. The total BOH in the sample, 
which represented the sum of any BDP, 17-monopropi- 
onate, 21-monopropionate and BOH present, was mea- 
sured with the BOH assay. The method used to 
determine total BOH was linear over the calibration 
range 0.036-0.709 ng ml-l. Details of the accuracy and 
precision of the BOH assay have been published (5). 
Non-compartmental pharmacokinetic analyses were 
performed on the serum level data. The maximum 
serum concentration (C,,,) and the area under the 
serum concentration-time curve (AUC) were the pri- 
mary pharmacokinetic parameters in all the studies 
carried out. Statistical analyses were done on the loga- 
rithmically transformed data using analysis of variance 
methods appropriate for the cross-over design in stud- 
ies A and B or using Jonckheere’s test for increasing 
trend in study C. Standard methods for equivalence 
testing were employed. T,,, defined as the time of 
C max, was also calculated. 
Additional details of the studies have been pub- 
lished elsewhere (668). 
Single-dose Pharmacokinetics 
Serum levels of total BOH and BOH were measured 
following two doses of HFA-BDP in study A. From 
the results, it is clear that most of the BDP measured 
in the serum was derived from BDP directly and/or the 
monopropionate esters, not BOH (Fig. 1). The mean 
total BOH levels peaked much sooner and at least one 
order of magnitude higher than those of BOH. 
Cm,, and AUC values for total BOH and BOH after 
inhalation of 400 pg HFA-BDP were approximately 
twice as high as those obtained after inhalation of 
200 yg HFA-BDP (Table 2). The statistical criteria for 
linear proportionality were met in three of the four 
comparisons, implying that reducing the dose in half 
would give an equivalent reduction of the pharmaco- 
kinetic parameters (Table 3). 
Steady-state Pharmacokinetics 
A second study, study B, examined the pharmaco- 
kinetics of total BOH following the first and 27th 
(steady-state) doses of three HFA-BDP dose levels 
(Fig. 2). All doses were administered twice daily for 14 
days. The good proportionality of the pharmaco- 
kinetic parameters on day 1 among the three HFA- 
BDP doses was similar to that observed following a 
single dose in study A. Good proportionality was also 
observed following the 27th (steady-state) dose as well 
as following the first dose, as shown by C,,, (Fig. 3). 
Study B also evaluated whether or not BDP and 
metabolites would accumulate to any significant extent 
in the serum on multiple dosing. Only small differ- 
ences in serum concentrations of total BOH were 
seen between day 1 and day 14, suggesting little accu- 
mulation on multiple dosing. Approximately 33% 
accumulation would have been predicted for a drug 
TABLE 2. Comparative total BOH pharmacokinetic parameters from study 
A; values are mean (SD) 
Parameter HFA-BDP HFA-BDP 
200 l-Q 400 !a 
Cmax (ng ml-9 0.590 (0.200) 1.191 (0.385) 
AUC (ng h ml-r) 2.339 (0.634) 4.962 (1.309) 
LGm 0.6 (0.3) 0.8 (0.5) 
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TABLE 3. Proportionality testing of HFA-BDP MDIs in study A 
Cm,, (ng ml-9 AUC (ng h ml-i) 
Total BOH BOH Total BOH BOH 
Geometric mean 400 l.tg HFA-BDP* 0.5643 0.0333 2.4094 0.3297 
Geometric mean 200 pg HFA-BDP 0.5580 0.0329 2.2469 0.2834 
Ratio (400* : 200) 1.01 1.01 1.07 1.16 
90% confidence interval for ratio 0.90-1.14 0.91-1.13 0.95-1.21 1.01-1.34 
Maximum P value? 0.003 <0~0001 0.016 0.20 
*Values divided by 2. 
S-P value < 0.05 indicates that treatments met the definition of equivalence. 
(a) 
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FIG. 2. Mean total BOH serum concentrations on (a) day 1 (single dose) and (b) day 14 (steady-state) of 
HFA-BDP multiple dosage regimens (0, 100 pg; A, 200 l..tg; 0, 400 pg): doses administered every 12 h. 
with a 6 h half-life which is dosed every 12 h. A 6 h 
half-life appears to be a reasonable estimate for the 
elimination of beclomethasone 17-monopropionate 
which, being the main component in the serum, is the 
one most likely to show accumulation. The observa- 
tion of similar curves in Fig. 2 for the data gathered on 
the first and 27th (steady-state) doses is important 
because it shows that all doses were affected as 
predicted; the magnitude of the effect was a 1040% 
increase on average in serum levels and Cm,, at 
steady state (Fig. 3), which was as predicted from 
pharmacokinetic principles and was without clinical 
consequence. 
Comparison with Chlorofluorocarbon- 
Beclomethasone Diproprionate 
CFC-BDP (BecloventTM, Allen & Hanburys) was 
included as a treatment in studies A and B, thus allow- 
ing a pharmacokinetic comparison of both single- 
dose and steady-state doses with the two propellant 
formulations. In study A, C,, and the AUC of total 
BOH following a 400 ltg CFC-BDP dose more closely 
resembled those following the 200 ltg HFA-BDP 
dose than those following the 400 ng dose (Fig. 4). 
However, C,,, was significantly lower and Tmax was 
significantly later with CFCBDP. 
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FIG. 3. Comparison of total BOH C’,,, values on day 
1 (cl; single dose) and day 14 (W; steady-state). 
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FIG. 4. Comparative mean serum total BOH concen- 
trations following single inhaled doses of HFA-BDP 
(m; 200 pg) or CFC-BDP (0; 400 pg). 
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FIG. 5. Comparative mean serum concentrations of total BOH on (a) day 1 (single dose) and (b) day 14 (steady- 
state) following multiple dosage regimens with HFA-BDP (A; 200 pg) or CFC-BDP (*; 400 pg): doses adminis- 
tered every 12 h. 
A comparable pattern was obtained in study B, a 
multiple dosing study, in which similar serum levels 
and pharmacokinetic parameters of total BOH were 
observed between 400 Fg CFC-BDP and half that 
dose administered as HFA-BDP (Fig. 5). 
Relative Oral Absorption 
To clarify the differences in drug bioavailability be- 
tween the CFC-BDP and HFA-BDP products, study 
C was designed to determine the relative absorption of 
orally administered BDP compared with inhaled 
HFA-BDP Oral BDP capsules were prepared and 
administered as five doses. As with the inhaled 
HFA-BDP doses, good proportionality of the phar- 
macokinetic parameters for BOH was observed 
between the oral doses (Fig. 6). 
The oral doses that matched the BOH Cm,, and 
AUC of the two inhaled HFA-BDP reference doses 
were calculated. Oral doses of 500 pg and 2000 pg 
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FIG. 6. Mean BOH serum concentrations following 
oral BDP; a, 200 pg; 0, 500 ,ug; V, 1000 ug; 0,200O 
I.&; 0,5~00 l-4 
%-2- I I 
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FIG. 7. Oral doses which gave similar serum BOH 
concentrations to inhaled HFA-BDP; 0, 500 pg oral; 
0,200O pg oral; A, 200 l.tg MDI; W, 800 pg MDI. 
were determined as those required to give comparable 
pharmacokinetic parameters for BOH to the reference 
inhaled 200 1.18 and 800 pg HFA-BDP doses, which, 
by chance, were the oral doses used in the study (Fig. 
7). Thus, the oral route required 2.5 times more drug 
to give the same BOH serum levels and AUC than did 
inhaled HFA-BDP. This study also showed that Tmax 
for oral doses was later than for inhaled HFA-BDP, 
indicating a slower absorption with the oral route. 
Explanation of Observations: a Unifying 
Hypothesis Discussion 
Considering that orally administered BDP has been In vitro evidence of a higher mass of fine particles of 
shown to result in a slower and decreased absorption BDP delivered by an HFA solution aerosol suggested 
and reduced bioavailability compared with inhaled an in vivo benefit of improved deposition in the intra- 
HFA-BDP, the observed lower bioavailability of the pulmonary airways. A series of pharmacokinetic stud- 
CFC-BDP MD1 compared with the HFA-BDP MD1 ies in asthmatic patients was undertaken to investigate 
50 100 150 
Fine particle mass (pg) 
FIG. 8. Correlation between total BOH AUC and fine 
particle mass following HFA-BDP and CFC-BDP 
regression line and 95% confidence limits shown. 
can be explained if most of each inhalation from the 
CFC-BDP MD1 is swallowed and absorbed from the 
gastrointestinal tract, whereas most of the HFA-BDP 
MD1 is absorbed from the lungs. This supposition has 
been confirmed in deposition studies with these two 
propellant formulations, as described by Leach (9). 
Such studies have shown that approximately 90% 
of the ex-actuator dose from the CFC-BDP MD1 
is swallowed whereas about 60% of the ex-actuator 
dose from the HFA-BDP MD1 is deposited in the 
airways. The extensive oral deposition of the CFC 
product explains not only the lower extent of absorp- 
tion but also the lower rate of absorption with this 
formulation. 
The observed pharmacokinetic differences between 
the CFC-BDP and HFA-BDP MDIs were expected, 
based on the physical differences found between these 
products in fine particle mass. Our hypothesis that 
increased fine particle mass results in increased air- 
ways availability detected by increased drug absorp- 
tion was confirmed. Indeed, if the administered dose 
was calculated in terms of the fine particle mass 
expected to reach the airways rather than the absolute 
dose given to the patient, all the observed data 
for both propellant systems could be correlated 
with the amount of total BOH in the serum (Fig. 8). 
This observation shows that fine particle mass is a 
direct correlate of in viva pulmonary deposition and 
increased drug absorption. 
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the implications on the serum profile of BDP and 
metabolites. 
These studies demonstrated a serum level profile of 
BDP and active metabolites consistent with greater 
airways availability detected by an increased rate and 
extent of lung absorption from BDP extrafine aerosol 
compared with a CFC-BDP MDI. Fine particle mass 
showed a good correlation with the amount of BDP 
and active metabolites in the blood for both the 
HFA and the CFC formulations, providing strong evi- 
dence that delivery to the airways and serum profiles 
are largely related to the fine particle mass of BDP 
delivered to the patient. Consistent with the pharma- 
cokinetic results, twice as much CFC-BDP was 
required to achieve a similar fine particle mass as 
HFA-BDP. 
Considering that the airways are the target for the 
topical activity of BDP and metabolites, and that 
blood levels are a means to access the efficiency of 
delivering drug to the airways, the present results 
suggest that lower total daily doses of HFA-BDP 
extrafine aerosol will be required than withCFC-BDP. 
The potential beneficial implications of improved air- 
ways availability of HFA-BDP on its efficacy and 
safety in asthma are discussed elsewhere in this volume. 
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